TUSTIN, Calif., Dec. 5, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that the two abstracts it submitted to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were accepted for presentation from among 730 abstracts submitted. The meeting will be held on January 19-21, 2012 at the Moscone West Building in San Francisco, California. Dr. Afsaneh Motamed-Khorasani, the Director of Oncology at Radient, will be presenting the data.
These two abstracts were the results of a collaborative study in the United States that compared the combined use of Onko-Sure® with carcinoembryonic antigen (CEA), the routine blood biomarker for colorectal cancer (CRC), and CEA alone. The clinical trial included a total of 564 subjects. Radient's proprietary Onko-Sure® cancer blood test combined with CEA test were more effective for the detection of colorectal cancer compared to using CEA test alone (an increase of 56% in the test sensitivity). Furthermore, the combined usage of Onko-Sure® and CEA in monitoring CRC recurrence showed a significant clinical advantage in terms of sensitivity (an increase of 35% in the test sensitivity). This was in line with a previous UK study published in peer reviewed journals in 2010.
Onko-Sure® has already been cleared by the US FDA for the monitoring of the treatment and recurrence in CRC. "We believe that Onko-Sure® provides a platform technology that is highly effective in the monitoring of colorectal cancer. Should an in vitro diagnostics test increase early detection of CRC recurrence when used adjunctively with other available diagnostic markers, the number of annual deaths due to CRC recurrence could be reduced. An increase in early detection has the potential to lead to an increased survival rate of patients," stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan.
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail firstname.lastname@example.org. For Investor Relations contact Paul Knopick at: email@example.com or 949-707-5365.About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
E & E Communications
SOURCE Radient Pharmaceuticals Corporation